ADVFN - Advanced Financial Network.
HOME» NYSE » N » NVS Stock Price » NVS Stock News

Novartis Share News

 Novartis Ag Basel Stock Price
NVS Stock Price
 Novartis Ag Basel Stock Chart
NVS Stock Chart
 Novartis Ag Basel Stock News
NVS Stock News
 Novartis Ag Basel Company Information
NVS Company Information
 Novartis Ag Basel Stock Trades
NVS Stock Trades

Novartis CEO Sees Big Potential In Biosimilars

ZURICH -(Dow Jones)- Novartis AG (NVS) Chief Executive Joe Jimenez said Tuesday he sees potential in the market for biosimilars, cheaper versions of expensive and complex medicines made from biological matter. "This is a market that is relatively small today, but we expect that by 2020 this could be a 15 to 20 billion dollars segment of the generics business," Jimenez told analysts in a call. "Novartis is uniquely positioned in biosimilars because we have the scientific and medical expertise of a pharmaceutical company and the commercial expertise of a generics company," he said. Novartis has its own generics unit, Sandoz. Biosimilars are imitations of biotech drugs, ones that are basically interchangeable with a previously approved biologic but because of the inherent complexity of the products cannot be termed identical. -By Marta Falconi, Dow Jones Newswires; +41 43 443 8043; marta.falconi@dowjones.com

Stock News for Novartis (NVS)
DateTimeHeadline
04/25/201507:06:02Are Biosimilars the Next Big Thing in Biotech?
04/23/201518:21:48ADR Shares End Higher; Ericsson Drops, Logitech Rises
04/23/201512:49:55Eli Lilly Results Top Expectations
04/23/201512:44:52Eli Lilly Results Top Expectations
04/23/201512:32:22Novartis Begins to See Benefits of Overhaul -- 2nd Update
04/23/201506:59:03Novartis Begins to See Benefits of Overhaul -- Update
04/23/201503:58:06Novartis Profit Boosted by Disposals
04/23/201502:54:59Novartis Profit Boosted by Disposals
04/22/201519:20:35CSL Says CFO Naylor to Lead Influenza-Vaccine Business
04/22/201510:03:023 Soaring Biotech Stocks Under $10 -- Are They Buys?
04/20/201518:59:29Why Shares of Juno Therapeutics Inc. and Kite Pharma Inc. Crashed...
04/20/201517:43:06Novartis 1Q 2015 -- Forecast
04/19/201507:14:033 Megatrends in Healthcare
04/18/201509:19:03Meet the Game-Changing Drug Designed to Fight America's Leading...
04/16/201517:15:08Why Momenta Pharmaceuticals Inc. Shares Are Surging Higher
04/16/201516:51:37FDA Approves Generic Multiple-Sclerosis Drug by Novartis's Sandoz...
04/16/201516:07:15FDA Approves Novartis and Momenta's Generic Multiple-Sclerosis...
04/16/201508:58:023 Potential Blockbuster Drugs That Could Be Approved Before Year's...
04/15/201508:59:033 Biotech Stocks That May Disappear Before 2020
04/14/201508:44:32The Growing Business Of Animal Healthcare

Novartis and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad